JP2022535406A5 - - Google Patents
Info
- Publication number
- JP2022535406A5 JP2022535406A5 JP2021571834A JP2021571834A JP2022535406A5 JP 2022535406 A5 JP2022535406 A5 JP 2022535406A5 JP 2021571834 A JP2021571834 A JP 2021571834A JP 2021571834 A JP2021571834 A JP 2021571834A JP 2022535406 A5 JP2022535406 A5 JP 2022535406A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- days
- period
- dose
- subsequent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858076P | 2019-06-06 | 2019-06-06 | |
| US62/858,076 | 2019-06-06 | ||
| EP19193850.5 | 2019-08-27 | ||
| EP19193850 | 2019-08-27 | ||
| PCT/EP2020/065639 WO2020245365A1 (en) | 2019-06-06 | 2020-06-05 | Methods of treating cancer using prmt5 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535406A JP2022535406A (ja) | 2022-08-08 |
| JP2022535406A5 true JP2022535406A5 (enExample) | 2023-06-13 |
| JP7590351B2 JP7590351B2 (ja) | 2024-11-26 |
Family
ID=70922068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571834A Active JP7590351B2 (ja) | 2019-06-06 | 2020-06-05 | Ｐｒｍｔ５阻害剤を使用した癌の治療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11571437B2 (enExample) |
| EP (1) | EP3980019A1 (enExample) |
| JP (1) | JP7590351B2 (enExample) |
| KR (1) | KR20220017989A (enExample) |
| CN (1) | CN113966232A (enExample) |
| AU (1) | AU2020286961A1 (enExample) |
| BR (1) | BR112021024469A2 (enExample) |
| CA (1) | CA3142825A1 (enExample) |
| IL (1) | IL288665A (enExample) |
| JO (1) | JOP20210320A1 (enExample) |
| MA (1) | MA56095A (enExample) |
| MX (1) | MX2021014944A (enExample) |
| PH (1) | PH12021552841A1 (enExample) |
| SG (1) | SG11202112439YA (enExample) |
| TW (1) | TW202112375A (enExample) |
| WO (1) | WO2020245365A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022153161A1 (en) * | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| CN115161341B (zh) * | 2022-06-10 | 2023-07-21 | 中国人民解放军军事科学院军事医学研究院 | 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| WO2003070739A1 (en) | 2002-02-19 | 2003-08-28 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| EP1645561A1 (en) | 2003-07-15 | 2006-04-12 | Mitsui Chemicals, Inc. | Method of synthesizing cyclic bisdinucleoside |
| US20080033172A1 (en) | 2003-12-19 | 2008-02-07 | Koronis Pharmaceuticals, Incorporated | Mutagenic Heterocycles |
| EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| JP2009542608A (ja) | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| WO2010039548A2 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| WO2011075665A2 (en) | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2012083170A1 (en) | 2010-12-16 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| JP6510485B2 (ja) * | 2013-03-15 | 2019-05-08 | オハイオ・ステイト・イノベーション・ファウンデーション | Ｐｒｍｔ５インヒビターおよびそれらの使用方法 |
| JP6510539B2 (ja) | 2014-01-09 | 2019-05-08 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン | 置換ベンゾオキサジン及び関連化合物 |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| BR112016030787B1 (pt) | 2014-07-01 | 2022-12-20 | Takeda Pharmaceutical Company Limited | Entidade química, composição farmacêutica e seu uso |
| EA031895B1 (ru) | 2015-02-24 | 2019-03-29 | Пфайзер Инк. | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| CN108884108B (zh) | 2016-03-10 | 2021-08-31 | 詹森药业有限公司 | 用于用作prmt5抑制剂的取代核苷类似物 |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| BR112019006414A2 (pt) | 2016-10-03 | 2019-06-25 | Janssen Pharmaceutica Nv | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 |
| SG11201907607VA (en) | 2017-02-27 | 2019-09-27 | Janssen Pharmaceutica Nv | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor |
| MX2020005944A (es) | 2017-12-08 | 2020-08-24 | Janssen Pharmaceutica Nv | Analogos espirobiciclicos novedosos. |
-
2020
- 2020-06-04 TW TW109118748A patent/TW202112375A/zh unknown
- 2020-06-05 KR KR1020227000036A patent/KR20220017989A/ko not_active Ceased
- 2020-06-05 AU AU2020286961A patent/AU2020286961A1/en not_active Abandoned
- 2020-06-05 EP EP20729788.8A patent/EP3980019A1/en not_active Withdrawn
- 2020-06-05 MX MX2021014944A patent/MX2021014944A/es unknown
- 2020-06-05 MA MA056095A patent/MA56095A/fr unknown
- 2020-06-05 JP JP2021571834A patent/JP7590351B2/ja active Active
- 2020-06-05 CA CA3142825A patent/CA3142825A1/en active Pending
- 2020-06-05 BR BR112021024469A patent/BR112021024469A2/pt unknown
- 2020-06-05 US US16/893,477 patent/US11571437B2/en active Active
- 2020-06-05 SG SG11202112439YA patent/SG11202112439YA/en unknown
- 2020-06-05 WO PCT/EP2020/065639 patent/WO2020245365A1/en not_active Ceased
- 2020-06-05 CN CN202080043244.1A patent/CN113966232A/zh active Pending
- 2020-06-05 PH PH1/2021/552841A patent/PH12021552841A1/en unknown
-
2021
- 2021-12-01 JO JOP/2021/0320A patent/JOP20210320A1/ar unknown
- 2021-12-05 IL IL288665A patent/IL288665A/en unknown
-
2023
- 2023-01-26 US US18/160,246 patent/US20230241087A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI854573B (zh) | 藥物組合物、其用途及癌症的治療方法 | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2024526145A5 (enExample) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| JP2024133474A5 (enExample) | ||
| JP6761852B2 (ja) | がん治療 | |
| TWI818120B (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| JP2006523216A5 (enExample) | ||
| JP2025540925A (ja) | 癌の治療におけるアゼノセルチブの断続的投与レジメン | |
| CA3034875C (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| JP2022544485A (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| TW202535477A (zh) | 抗ｂ７ｈ３抗體—藥物偶聯物治療癌症的方法 | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| JP6370801B2 (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| JP2022535406A (ja) | Ｐｒｍｔ５阻害剤を使用した癌の治療法 | |
| JP2023009250A (ja) | がんを処置するための方法 | |
| JP2007500240A (ja) | Ａｂｔ−７５１による持続投与レジメン | |
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| CN113840608A (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| TW202339726A (zh) | 用於治療癌症之與畢尼替尼(Binimetinib)併用之HDAC抑制劑OKI-179 | |
| KR20240046527A (ko) | 암치료를 위한 신규 경구용 약학적 조성물 | |
| US20250381190A1 (en) | Therapeutic combinations of capivasertib and venetoclax | |
| JP2009511535A (ja) | ５−（２−クロロフェニル）−１，２−ジヒドロ−７−フルオロ−８−メトキシ−３−メチル−ピラゾロ［３，４−ｂ］［１，４］ベンゾジアゼピン |